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1 PRD Risk Statement 
Future human exploration missions will require extended EVAs that will expose astronauts to 
hypobaric and hypoxic atmosphere conditions.   This can result in risk of compromised health 
and performance to the crewmember. 
2 Executive Summary 
Extravehicular activity (EVA) is at the core of a manned space exploration program. Some 
elements of exploration may be safely and effectively performed by robots, but certain critical 
elements will require the trained, assertive, and reasoning mind of a human crewmember. To 
effectively use these skills, NASA needs a safe, effective, and efficient EVA component 
integrated into the human exploration program. The EVA preparation time should be minimized 
and the suit pressure should be low to accommodate EVA tasks without causing undue fatigue, 
physical discomfort, or suit-related trauma. Commissioned in 2005, the Exploration 
Atmospheres Working Group (EAWG) had the primary goal of recommending to NASA an 
internal environment that allowed efficient and repetitive EVAs for missions that were to be 
enabled by the former Constellation Program. At the conclusion of the EAWG meeting, the 8.0 
psia and 32% oxygen (O2) environment were recommended for EVA-intensive phases of 
missions.  
 
After re-evaluation in 2012, the 8/32 environment was altered to 8.2 psia and 34% O2 to reduce 
the hypoxic stress to a crewmember. These two small changes increase alveolar O2 pressure by 
11 mmHg, which is expected to significantly benefit crewmembers. The 8.2/34 environment 
(inspired O2 pressure = 128 mmHg) is also physiologically equivalent to the staged 
decompression atmosphere of 10.2 psia / 26.5% O2 (inspired O2 pressure = 127 mmHg) used on 
34 different shuttle missions for approximately a week each flight. 
  
As a result of selecting this internal environment, NASA gains the capability for efficient EVA 
with low risk of decompression sickness (DCS), but not without incurring the additional negative 
stimulus of hypobaric hypoxia to the already physiologically challenging spaceflight 
environment. This report provides a review of the human health and performance risks 
associated with the use of the 8.2 psia / 34% O2 environment during spaceflight. Of most concern 
are the potential effects on the central nervous system (CNS), including increased intracranial 
pressure, visual impairment, sensorimotor dysfunction, and oxidative damage. Other areas of 
focus include validation of the DCS mitigation strategy, incidence and treatment of transient 
acute mountain sickness (AMS), development of new exercise countermeasure protocols, 
effective food preparation at 8.2 psia, assurance of quality sleep, and prevention of suit-induced 
injury. Although missions proposing to use an 8.2/34 environment are still years away, it is 
recommended that these studies begin early enough to ensure that the correct decisions 
pertaining to vehicle design, mission operational concepts, and human health countermeasures 
are appropriately informed. 
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3 Introduction 
Over the past several decades, NASA has operated spacecraft habitable elements and spacesuits 
at a variety of different atmospheres. Early missions during the Gemini and Apollo programs 
were short duration and relied on low-pressure, 100% O2 environments. Skylab missions were 
longer in duration but still employed a low-pressure (5 psia), 70% O2 environment. NASA’s 
more recent programs, including the Space Shuttle Program and International Space Station 
(ISS) program have operated at an Earth-equivalent sea level atmosphere of 14.7 psia and 21% 
O2. Selection of this atmosphere facilitated international partnerships and allowed in-flight 
scientific studies to have ground-based controls, with gravity as the primary variable of interest.  
 
In 2005, the EAWG was convened to formulate recommendations on the designs of habitable 
internal environments to inform requirements for the development of vehicles during the 
Constellation Program [1]. The process used to select among several candidate environments is 
detailed in the EAWG final report, which was first published as an internal NASA document [2] 
and then later as a NASA Technical Paper [1]. The primary trade space applied to the EAWG 
analysis for the lunar and Mars habitat and surface spacesuit designs consisted of hypoxia, 
flammability, and DCS. 
 
The 2006 EAWG recommendations were as follows: 
 Launch and transport vehicle should operate within the existing ISS and shuttle standard 
environment designs of 14.7 psia / 21% O2 and 10.2 psia / 26.5% O2  
 Lunar and Mars landers should operate at both 10.2 psia / 26.5% O2 and 8.0 psia / 32% 
O2 
 Surface spacesuits should operate at 100% O2 and at a pressure range of 3.5 to 8.0 psia 
 Long-duration lunar and Mars habitats should operate at 8.0 psia / 32% O2 nominally 
with an option to decompress further to 7.6 psia / 32% O2  
 Atmospheric recommendations assumed a control box of ± 0.2 psia total pressure and ± 
2.0% O2 concentration 
 
The consensuses of the EAWG were the recommendations for a lower-pressure surface habitat 
and a surface spacesuit with a variable operating pressure range. The 8 psia / 32% O2 (henceforth 
referred to as 8/32) environment was selected because it was considered to be a mildly hypoxic 
atmosphere with acceptable flammability risk and low O2 prebreathe (PB) overhead to maintain 
acceptable DCS risk [1]. The proposed forward work related to human physiology was almost 
solely related to DCS, with no mention of hypoxia research.  
 
The EAWG recommendations were developed through a multi-discipline working group and 
concurred upon by the heads of the Johnson Space Center (JSC) Engineering, Space and Life 
Sciences, and Flight Crew Operations Directorates as well as the manager of the JSC 
Extravehicular Activity Office. However, attempts to move forward with vehicle designs based 
on the EAWG report were met with mixed approval because the recommendations were not 
captured anywhere outside of the Constellation Program documentation. The Exploration 
Atmosphere Action Team convened in 2012 to review the 8/32 atmospheric recommendation 
and moved to alter the environment to 8.2 psia and 34% O2 to reduce the hypoxic stress without 
affecting DCS risk or materials concerns [3]. This recommendation was presented to the NASA 
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Human Exploration and Operations Mission Directorate (HEOMD) Associate Administrator, 
who then provided a memorandum that directed programs under HEOMD to begin the work to 
enable the updated Exploration Atmosphere of 8.2 psia and 34% O2 [4]. 
 
3.1 Why and When 8.2/34 
Multiple reasons were proposed for the use of the 8.2/34 environment.  A primary benefit of this 
atmosphere is a reduction in O2 PB time for EVA since atmospheric ppN2 would decrease from 
11.6 psia in a 14.7/21 environment to 5.4 psia in a 8.2/34 environment. This minimizes the 
difference between tissue ppN2 and the lowest anticipated suit pressure of 4.3 psia.  With the 
8.2/34 option, it is expected that a 15-minute PB may be all that is necessary to achieve 
acceptable risk of DCS during EVA. An 8.2 psia cabin pressure also allows operational use of a 
suitport, which greatly reduces the complexity and overhead associated with EVA suit donning. 
The current expectation is that an astronaut could don the EVA suit through a suitport and 
complete all necessary checkout procedures and EVA prep during this 15-minute PB window. 
Additionally, suitport-compatible suits are proposed to be variable-pressure suits capable of 
operating from the 8.2 psia cabin pressure down to the expected EVA-operating suit pressure of 
4.3 psia. A variable-pressure suit also provides immediate treatment capability for DCS because 
the suit could be repressurized to 8.2 psia in the field without requiring reentry into the cabin. 
Furthermore, the short transition times between suit and cabin allow for intermittent 
recompressions, further reducing the risk of DCS. 
 
Beyond the control of DCS to acceptable risk levels, the 8.2/34 environment coupled with 
suitport operations is a paradigm shift from NASA’s ISS and shuttle EVA protocols. Unlike the 
ISS construction and maintenance EVAs, which were well understood and very specific, 
exploration EVAs will be driven by choices made at the destination. Exploration crews need a 
robust and flexible EVA capability, which is provided by coupling the 8.2/34 environment with 
suitport operations. This combination provides an on-demand EVA capability including short-
duration EVA, multiple EVAs per day, and single-person EVA. 
 
Application of the 8.2/34 environment is only needed during high EVA-frequency phases of a 
mission. The 8.2/34 environment is not needed for launch or transit to the destination, although 
the capability should be considered for all habitable elements to ensure transitions between 
different elements can be accomplished during contingency situations. Currently, any element 
expected to operate in the 8.2/34 environment (other than the EVA suit) will also be capable of 
repressurizing and operating at 14.7/21.  
 
3.2 Important Changes since the 2006 EAWG Final Report 
Much has changed at NASA since the 2006 EAWG recommendations, including cancellation of 
the Constellation Program, development of the Multi Mission Space Exploration Vehicle 
(MMSEV) concept, movement toward a Capability-Driven Framework for space exploration, 
advances in our understanding of human adaptation to the spaceflight environment, and the 
identification of new human risks and hazards.  
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3.2.1 Constellation Program Cancellation 
One of the largest changes since the EAWG was the cancellation of the Constellation Program. 
This program featured a clear target of the moon with rapidly evolving operational concept 
development. The requirement for an Exploration Atmosphere of 8/32 was kept in the 
Constellation Architecture Requirements Document. It is difficult to quantify how much this 
affected implementation of the EAWG recommendations for vehicle requirements, research, and 
development. It could be that discontinuity with personnel in the intervening years coupled with 
a change from a well-defined lunar target to a capability-driven framework contributed to some 
of the concerns about using the EAWG report as an approved baseline.  
 
3.2.2 MMSEV and Suitport Development 
Over this same time period, new space exploration vehicles and spacesuits were designed and 
developed in accordance with the recommendations from the EAWG. One of these vehicles is 
the MMSEV, which began as a small pressurized rover for the lunar environment. It has since 
developed additional capability beyond lunar and Mars surface operations to now include 
variants with operating capacity in the microgravity environment as well, either as a way-station 
habitat or as a near-Earth asteroid (NEA) exploration vehicle. The MMSEV assumed the 8/32 
environment as the NASA baseline and has developed both a suitport and a variable-pressure 
rear-entry suitport-compatible EVA suit. Use of a variable-pressure EVA suit with suitport 
enabled by the 8/32 internal environment yields several benefits. From an operational standpoint, 
NASA gains the capability for single-person EVA, short EVA, multiple EVAs in a single day, 
enhanced waste removal using a suitport transfer module, reduced consumables, and high work 
efficiency index. In terms of safety, there is reduced overhead for meeting acceptable DCS risk, 
multiple vehicle reentry points, and immediate capability for DCS treatment through 
repressurization of the EVA suit.  
 
3.2.3 Independent Pressure Effect on Hypoxic Dose 
Although not a new debate, recently, there has been considerable discussion on whether 
normobaric hypoxia (NH) elicits the same hypoxic symptoms as hypobaric hypoxia (HH) [5] [6] 
[7]. In many cases, the differences may not reach statistical or clinical significance, but the 
general trend indicates that almost all measurable changes associated with hypoxic exposures 
trend worse in the case of HH compared with NH for the same hypoxic PIO2. Given that the 8/32 
environment is an engineered environment and does not exist in nature, a standard equivalent air 
altitude (EAA) may not be fully representative of the hypoxic stress. An 8 psia atmospheric 
pressure (PB) is associated with an actual altitude of 4,877 m (16,000 ft).  It is the enrichment of 
O2 from 21% to 32% that reduces the hypoxic stress to an EAA of approximately 1,830 m (6,000 
ft).  It is unknown whether the increased hypobaric exposure will increase the hypoxic dose, but 
at least one literature review suggested that the 8/32 environment increased the risk of AMS 
from the proposed EAA of approximately 1,830 m (6,000 ft) to 2896 m (9,500 ft) [8]. This 
hypothesis is based on a literature review and a proposed model and has not been validated, but it 
does point to the need for human exposure research in the 8/32 environment. A more recent 
review lends further support that NH and HH are not equivalent for acute and subacute 
exposures and suggests that using NH as a surrogate for HH during chronic exposures is 
inappropriate [9]. 
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Research is warranted to evaluate a possible PB effect on hypoxic adaptations.  Results from 
these studies will aid in the understanding of human physiology in the proposed 8.2/34 
environment as well as inform the scientific community on how best to proceed with hypoxia 
research. In research settings, it is easier to design and operate systems that manipulate PIO2 by 
reducing FIO2 at 14.7 psia rather than reducing PB with or without O2-enrichment. However, in 
situations where the PB effect is significant, human or animal research will require true ascent-to-
altitude or hypobaric chamber studies. 
 
3.2.4 Visual Impairment / Intracranial Pressure Syndrome 
Because of its prevalence and potential mission impact, visual impairment / intracranial pressure 
(VIIP) is considered the top human system risk in the ISS Program. Currently, VIIP is a poorly 
understood syndrome with potential for permanent damage to the ocular and central nervous 
systems. The changes that have been observed to date are developing in microgravity without 
additional exposure to HH. While the pathophysiology of VIIP is under active investigation, the 
addition of HH to the spaceflight environment may exacerbate the problem.  
 
3.2.5 Elevated Carbon Dioxide on ISS 
Elevated carbon dioxide (CO2) is a known problem in a closed system with humans in the loop. 
On Earth, the ambient CO2 concentration is approximately 0.23 mmHg (0.03%). In spacecraft, it 
is not practical to control CO2 to such low levels because of power and consumable constraints, 
and CO2 levels on the ISS have typically been 2.3 to 5.3 mmHg (0.5 ± 0.2%), a ten-fold increase 
compared with terrestrial levels [10]. Over the years, ISS crewmembers have been found to 
develop CO2-related symptoms, such as headache and lethargy, at lower-than-expected CO2 
levels, and symptoms tend to resolve when ambient CO2 is decreased [11]. While work to 
quantify this association is ongoing, chronic CO2 exposure appears to be a contributing factor to 
several in-flight medical issues, including VIIP [11] [12]. The CO2 elevation will likely 
complicate the adaptation to a mildly hypoxic environment, potentially making physiological 
symptoms worse. 
4 Evidence for Hypoxia-Induced Physiological Concerns 
This section will discuss the physiological concerns and impacts related to the mild hypoxic 
atmosphere of the 8.2/34 environment. Decreasing the O2 delivery to all the bodily organs and 
systems has an impact on all physiological functions. However, the 8.2/34 environment only 
induces a mild hypoxic stimulus, which we would not be concerned about in itself on the surface 
of the Earth. We know that humans adapt well to altitude with a similar ambient O2 partial 
pressure as the 8.2/34 environment, with millions of people residing at altitudes greater than 
4000 ft and even more people transiently experiencing mild hypoxia during airplane flights 
ranging from 5000-8000 ft. Such an environment in combination with other spaceflight factors, 
such as microgravity and space radiation, is of concern because the additive and/or synergistic 
effects might impair human health and performance to an unacceptable risk level. In particular, 
the effects on brain and ocular physiology are of concern because we lack knowledge as to how a 
decrease in ambient O2 partial pressure – however small – in space might affect the pressure in 
the brain and eyes and thus human performance. In addition, we do not know how the 
combinatorial effects of a mildly hypoxic atmosphere and mildly hyperoxic EVA suit 
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atmosphere affect cellular pathways and whether they induce oxidative stress and damage, 
threatening human health to an unacceptable level. Consequently, the addition of mild hypoxia 
and its effect on the human system will be needed to augment existing NASA human research. 
Particular emphasis should be placed on brain and ocular function, sensorimotor performance, 
and cellular oxidative stress and damage. 
 
4.1 Hypobaric Hypoxia in Space 
The use of a mildly hypobaric hypoxic environment has been used for short-term exposures to 
facilitate EVA during both the shuttle and ISS programs. One serendipitous finding was that 
8.2/34 is almost physiologically equivalent to the atmosphere of 10.2 psia and 26.5% O2 used on 
the shuttle. A comparison of the two environments is shown in Table 1, demonstrating that the 
two environments are almost equivalent with respect to the hypoxia level, but that 8.2/34 
presents a much lower tissue N2 saturation level.  
 
Any human health and performance data available from missions employing the 10.2/26.5 
environment may be helpful toward understanding the implications of employing a mildly 
hypoxic environment during flight. Table 2 describes the number of days at 10.2/26.5 as well as 
the crew size and total man-days. Days at 10.2/26.5 were calculated though a data mining 
process using the Archive Data Retrieval (ADRIFT) subprogram in the Java Mission Evaluation 
Workstation System (JMEWS) data system.   
The average duration at 10.2/26.5 was 3.48 days, with 24 of the 33 missions decompressing to 
10.2/26.5 for less than 4 days. The longest mission using 10.2/26.5 was STS-61, which 
decompressed for 8.1 consecutive days.  
Data mining efforts using both the Lifetime Surveillance of Astronaut Health (LSAH) and Life 
Sciences Data Archive (LSDA) are underway to evaluate whether there are any crew medical 
complaints related to hypoxia or if there are any past studies that may have data across both 10.2 
and sea-level Shuttle missions. 
Table 1. Comparison of the 8.2/34 Environment to the Shuttle 10.2/26.5 Atmosphere 
PB 
psia 
O2% 
ppO2  
mmHg 
PAO2 
mmHg 
EAA 
m (ft) 
ppN2 
(mmHg) 
10.2 26.5 140 87 1265 (4150) 388 
8.2 34 144 88 1213 (3980) 280 
Difference +4 +1 -170 -108 
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4.2 VIIP Syndrome 
Because of its prevalence and potential mission impact, visual impairment / intracranial pressure 
(VIIP) is considered the top human system risk in the ISS Program. Currently, VIIP is a poorly 
understood syndrome with potential for permanent damage to the ocular and central nervous 
systems. The changes that have been observed to date are developing in microgravity without 
Table 2. Spaceflight Experience with the 10.2 psia / 26.5% O2 Environment 
Flight Launch Landing 
Crew 
Size 
Last EVA 
Days at 
10.2/26.5 
Man Days at 
10.2/26.5 
STS-41B 02/03/1984 02/11/1984 5 02/09/1984 3.32 16.58 
STS-41C 04/06/1984 04/13/1984 5 04/11/1984 4.83 24.13 
STS-41G 10/05/1984 10/13/1984 7 10/11/1984 1.36 9.54 
STS-51A 11/08/1984 11/16/1984 5 11/14/1984 3.74 18.70 
STS-51D 04/12/1985 04/19/1985 7 04/16/1985 2.10 12.60 
STS-51I 08/27/1985 09/03/1985 5 09/01/1985 2.87 14.34 
STS-61B 11/26/1985 12/03/1985 7 12/01/1985 3.14 21.95 
STS-37 04/05/1991 04/11/1991 5 04/08/1991 2.92 14.59 
STS-49 05/07/1991 05/16/1992 7 05/14/1992 7.13 49.92 
STS-54 01/13/1993 01/19/1993 5 01/17/1993 2.28 11.40 
STS-51 09/12/1993 09/22/1993 5 09/16/1993 2.74 13.70 
STS-61 12/02/1993 12/13/1993 7 12/08/1993 8.10 56.68 
STS-64 09/09/1994 09/20/1994 6 09/16/1994 1.33 7.99 
STS-69 09/07/1995 09/18/1995 5 09/16/1995 1.97 9.86 
STS-72 01/11/1996 01/20/1996 6 01/17/1996 3.70 22.21 
STS-76 03/22/1996 03/31/1996 6 03/27/1996 0.77 4.62 
STS-82 02/11/1997 02/21/1997 7 02/17/1997 7.18 50.28 
STS-87 11/19/1997 12/05/1997 6 12/03/1997 1.63 9.78 
STS-88 12/04/1998 12/15/1998 6 12/12/1998 7.76 46.59 
STS-96 05/27/1999 06/06/1999 7 05/29/1999 2.53 17.73 
STS-103 12/19/1999 12/27/1999 7 12/24/1999 5.23 36.58 
STS-101 05/19/2000 05/29/2000 7 05/21/2000 1.10 7.72 
STS-106 09/08/2000 09/20/2000 7 09/17/2000 0.79 5.54 
STS-92 10/11/2000 10/24/2000 7 10/18/2000 3.89 27.20 
STS-97 11/30/2000 12/11/2000 5 12/07/2000 5.88 29.42 
STS-98 02/07/2001 02/20/2001 5 02/14/2001 3.95 19.77 
STS-102 03/08/2001 03/21/2001 7 03/12/2001 1.73 12.13 
STS-100 04/19/2001 05/01/2001 7 04/24/2001 2.50 17.53 
STS-104 07/12/2001 07/24/2001 5 07/17/2001 1.92 9.62 
STS-105 08/10/2001 08/22/2001 4 08/18/2001 1.41 5.65 
STS-108 12/05/2001 12/17/2001 7 12/10/2001 0.81 5.68 
STS-109 03/01/2002 03/12/2002 7 03/08/2002 7.32 51.26 
STS-125 05/11/2009 05/24/2009 7 05/18/2009 6.97 48.81 
Total 114.93       712.24 
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additional HH exposure. While the pathophysiology of VIIP is under active investigation, the 
addition of HH to the spaceflight environment may exacerbate the problem.  
 
4.2.1 VIIP during Spaceflight 
The VIIP syndrome was first described in 2006 with the observation of papilledema, vision 
changes, and increased intracranial pressure in long-duration astronauts returning from the ISS. 
However, post-flight questionnaires obtained between 1989 and 2011 revealed that 23% of 
shuttle and 48% of ISS long-duration mission astronauts reported a subjective degradation in 
vision [13], suggesting that spaceflight-induced visual impairment and intracranial hypertension 
may have been occurring in astronauts although the syndrome was not recognized until the 
technology advanced sufficiently to evaluate and look for it [14]. Based on a case definition 
developed by expert consensus, 15 cases have been identified among the 36 long-duration 
astronauts to date, although not all of these 36 astronauts have been fully evaluated. Although 
direct in-flight measurements have not been made, in-flight signs of papilledema and post-flight 
changes in brain imaging have documented evidence of elevated intracranial pressure (ICP). In 
addition, post-flight lumbar puncture in four ISS crewmembers has indicated elevated ICP 
ranging from 21.0 to 28.5 cmH2O (normal range: 5 to 15 cmH2O). Of note, ICP may remain 
elevated long after flight in some of the returning symptomatic astronauts, over 18 months in one 
case [13]. 
Microgravity exposure induces a cephalad fluid shift likely resulting in elevated ICP. It is 
possible that the cephalad fluid shift accounts for a 50% increase in ICP in the microgravity 
environment compared with 1-g [15]. In addition, it is known that the average CO2 level is 
elevated on the ISS, which may further increase ICP due to its potent vasodilator effects. Up to 
an additional 12% increase in ICP may be attributed to current CO2 levels on ISS [16]. Thus, a 
combination of the microgravity-induced cephalad fluid shift and high ambient CO2 levels very 
likely increases ICP in astronauts, leading to known visual acuity problems and possible impacts 
on cognitive brain function.  
 
4.2.2 VIIP and Hypoxia 
One concern associated with HH alone is the incidence of AMS (to be discussed further in 
Section 4.4), which lies within the spectrum of high-altitude headache to high-altitude cerebral 
edema. High-altitude cerebral edema is associated with increased ICP [17] [18] [19]. AMS itself 
appears to be strongly associated with increased optic nerve sheath diameter, reflecting increased 
ICP [20]. Sutherland et al. found that the optic nerve sheath diameter increased in 13 
mountaineers from sea level to exposures at 2000, 3700, 5200, and 6400 m (6562, 12139, 17060, 
and 20997 ft) [21]. Increased optic nerve sheath diameter has been found to correlate positively 
with ICP based on the fact that the subarachnoid cerebrospinal fluid (CSF) compartment 
communicates with the perioptic CSF space. Therefore, increases in intracranial CSF pressure 
are transmitted to the perioptic CSF space and may be measured as changes in the optic nerve 
sheath diameter. More directly, Yang, et al. found that upon exposure to an altitude of 4,000 m 
(13,123 ft) for 2 hours, ICP measured by an intraventricular catheter increased by 78% from 15.4 
to 27.4 cmH2O in hypoxic goats compared with nonhypoxic goats [22]. Physiologically, any 
decrease in O2 delivery results in vasodilation of cerebral vessels to increase brain blood flow 
and elevate ICP. With the addition of microgravity-induced intracranial hypertension, it is likely 
that astronauts would develop greater increases in ICP in an 8.2/34 environment than in 14.7/21. 
Even limited exposures to 8.2/34 may exacerbate VIIP in an additive or synergistic manner. 
Risk of Hypoxia from the Exploration Atmosphere 
12 
 
 
Moreover, in the setting of papilledema, hypoxia is expected to worsen optic nerve ischemia. 
Hypoxia at altitude is associated with optic disc swelling, hypothesized to be due to a hypoxia-
induced increase in cerebral blood flow that disrupts the blood-brain barrier and results in 
cerebral edema [23] [24]. Altitude-associated optic disc swelling has been described since 1969 
[19]; a recent study of 27 high-altitude mountaineers by Bosch, et al. [23] revealed optic disc 
swelling in 59% of the climbers. Furthermore, high-altitude retinopathy, typically described as 
retinal vascular engorgement and tortuosity, has been associated with decreased visual acuity and 
cotton wool spots [25], two of the diagnostic hallmarks of VIIP [14]. There is enough overlap 
between spaceflight-induced VIIP and altitude illnesses to warrant precaution about intentionally 
adding HH to spaceflight. The concern is that an 8.2/34 environment would worsen visual 
changes, potentially leading to a decreased ability to perform tasks and possible permanent 
damage. 
 
4.2.3 VIIP Conclusion 
Currently, 42% of ISS crewmembers are affected by the VIIP syndrome, 15% of whom are 
severely affected, in a normobaric, normoxic (14.7 psi / 20.9% O2) environment. Because of its 
prevalence and potential mission impact due to visual and CNS impairment, VIIP is considered 
the top human system risk in the ISS Program. It should be noted that the changes that have been 
observed to date are developing in microgravity without additional exposure to HH. The 
combinatorial effects of spaceflight environmental factors, such as microgravity and high 
ambient CO2 levels, with an 8.2/34 environment are unknown and could potentially negatively 
impact brain blood flow and cognitive abilities based on current knowledge of the VIIP 
syndrome.  
 
4.3 Sensorimotor Performance 
Sensorimotor disturbances are well known to occur during spaceflight, and these changes may be 
exacerbated by the introduction of HH with the 8.2/34 environment. 
4.3.1 Sensorimotor Performance during Spaceflight 
Astronauts experience disturbances in sensorimotor function during periods of adaptive change 
on initial exposure to microgravity and on return to a gravity environment. These disturbances 
include spatial disorientation, space motion sickness, alterations in gaze control, and postflight 
postural instability and gait ataxia [26] [27] [28] [29] [30] [31]. Importantly, sensorimotor 
disturbances are more profound as the duration of exposure to microgravity increases. These 
changes can impact in-flight operational activities, including spacecraft landing, docking, remote 
manipulation, and EVA performance. In addition, postflight postural and gait instabilities could 
prevent or extend the time required to make a nominal or an emergency egress from a spacecraft. 
 
4.3.2 Sensorimotor Performance and Hypoxia 
The retina is extremely sensitive to changes in O2; therefore, acute hypoxia can lead to 
decrements in visual function. These changes are less profound in the mild hypoxic range; 
however, performance decrements have been observed [32]. In one study that focused on visual 
performance specifically in the hypoxic range of 1,830 to 2,438 m (6,000 to 8,000 ft), mesopic 
vision was impaired [33]. Mesopic vision refers to visual performance under low-light but not 
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quite dark conditions, equivalent to those experienced during twilight. Given potential low-light 
conditions during planetary operations, this decrease in visual performance may have operational 
implications.  
 
Mild hypoxia has also been shown to have an effect on the postural control system [34] [35] 
[36]. Postural sway measured in subjects standing on a force plate was shown to increase 
compared with ground-level controls at simulated altitudes of 1,524, 2,438, and 3,048 m (5,000, 
8,000, and 10,000 ft) [34]. The postural control system receives input from several sensory 
modalities, including information from vision; the vestibular system; proprioception from joints, 
tendons, and muscles; and tactile information. These multiple sensory informational sources are 
integrated in the CNS to aid in the control of postural equilibrium. Therefore, a change in 
postural equilibrium control can serve as a sensitive indicator of mild hypoxic effects on multiple 
sensory systems along with the efficacy of their central integration. 
 
In terms of pilot flight control performance, exposure to mild hypoxia does not have a significant 
impact on manual control ability for tasks such as maintaining assigned altitudes and navigation; 
however, procedural errors appear to increase at the 3,048-m (10,000-ft) level [37]. These events 
include misdialing frequency codes and failure to follow air traffic control instructions. In a 
study using self-report questionnaires to assess hypoxic symptoms of helicopter aircrew 
operating at altitudes below 3,048 m (10,000 ft), aircrew reported potentially operationally 
significant symptoms of hypoxia at a mean altitude of 2,590 m (8,497 ft) [38]. 
 
During gravitational transitions, sensorimotor systems undergo adaptive changes to match motor 
output to the prevailing environment. It is currently unknown what the impact of hypoxia is on 
this essential process of sensorimotor adaptive change. Does hypoxia hinder the adaptive 
response, thereby prolonging the period of sensorimotor disturbance experienced during 
gravitational transitions? If hypoxia interacts negatively with the nominal sensorimotor adaptive 
process, performance decrements, including changes in dynamic visual acuity, postural and gait 
instability, and spatial disorientation, may be exacerbated, impacting performance and mission 
success. In addition, there are well-known vestibular-evoked responses recorded from respiratory 
muscle nerves that serve to provide adjustments in breathing and airway patency during 
movements and changes in posture [39]. It is possible that vestibular adaptation shortly following 
G-transitions may negatively impact the respiratory compensation in the 8.2/34 environment. 
Singh, et al. [40] observed that altered vestibular function, such as increased sway at high 
altitudes, may reverse with acclimatization. Therefore, sensorimotor interactions with the 8.2/34 
environment are likely to be more important within the first few days following the transitions 
between G states. 
 
4.3.3 Sensorimotor Performance Conclusion 
From a sensorimotor perspective, mild hypoxia can induce alterations in performance, including 
visual and postural stability decrements and some alterations in piloting ability. These effects are 
not profound in terms of overall impact on performance; however, in combination with other 
factors unique to spaceflight, these performance decrements may reach the threshold of 
impacting mission capability. 
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To determine whether sensorimotor adaptive mechanisms are negatively affected by the 8.2/34 
environment, the following studies could be performed to compare the normoxic adaptive 
response with the 8.2/34 hypoxic environment: 
 
 Gaze control and dynamic visual acuity adaptive responses to vision-distorting lenses 
(e.g., magnifying, minifying) 
 Manual control adaptive responses to modified joystick input 
 Gait adaptation to an unstable walking support surface 
 Combined effects of multitasking and increased G (entry profile) on adaptive 
responses 
 
If performance decrements are observed that are related to hypoxic-derived reductions in the 
adaptation ability of sensorimotor systems, countermeasures could be developed to mitigate 
these changes. One potential countermeasure entails hypoxic preconditioning training [41] [42] 
[43]. This training paradigm engages the endogenous mechanisms by which the brain protects 
itself against cerebral ischemia by exposing the subject to a noxious stimulus near to but below 
the threshold for damage. Following the preconditioning training, a tolerance is developed to the 
same or even different noxious stimulus beyond the usual threshold for effect. This type of 
training has been used successfully to develop an increased tolerance for ischemic stress. In this 
context, preconditioning to mild hypoxia could be used as a training countermeasure to reduce 
the hypoxic performance decrements associated with exposure to mild hypoxia and adaptive 
sensorimotor responses. 
 
4.4 Acute Mountain Sickness  
AMS affects individuals that ascend rapidly to altitude, with symptoms such as headache, 
nausea, vomiting, disturbed sleep, and poor physical performance [44]. The acute change in 
ambient ppO2 from normoxic (159 mmHg) to the ppO2 of 144 mmHg associated with the 8.2/34 
environment can result in the possibility that some crewmembers may develop transient 
symptoms of AMS. Between 7% and 25% of adults may experience mild AMS near 2,000 m 
(6,562 ft) [44] [45]. The risk of AMS is modified by several factors, including the ascent rate to 
altitude, activity level at altitude, and individual susceptibility [46]. HH appears to induce AMS 
to a greater extent than does either normobaric hypoxia or normoxic hypobaria [47].  
 
AMS symptoms have been recorded using the Lake Louise symptom questionnaire (LLSQ) and 
include headache plus nausea, dizziness, fatigue, or sleeplessness that develops over a period of 
6 to 24 hours. While expected to be mild and transient, these symptoms could potentially impact 
crew health and performance on critical mission tasks during lunar surface missions. AMS 
headaches are reported to be throbbing, bi-temporal, or occipital, typically worse during the night 
and upon awakening. Such headaches have implications for sleep quality. When combined with 
nausea, they can be likened to the flu or a hangover. Clinical findings confirm a change in mental 
status, ataxia, peripheral edema, or changes in performance (reduction in normal activities) [44]. 
 
One of the largest studies on AMS was conducted by Anderson, et al. [48] during rapid ascent to 
the Amundsen-Scott South Pole Station (2,835 m [9,300 ft]) in Antarctica. Of 246 subjects, 52% 
developed LLSQ-defined AMS (Figure 1). Anderson et al. are currently working on some 
follow-up manuscripts that will describe the known physiological differences between the 
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subjects who reported AMS and the subjects who had no AMS symptoms. The most common 
symptoms were shortness of breath with activity (87%), sleeping difficulty (74%), headache 
(66%), fatigue (65%), and dizziness/lightheadedness (46%) (Figure 2). Symptom reports at the 
South Pole were mild to moderate in severity, with symptom prevalence peaking on the day after 
arrival at altitude (day 2, approximately 12 to 18 hours after arrival); however, in greater than 
20% of individuals, shortness of breath with activity, fatigue, and sleep problems persisted 
through day 7. This result reflected conventional knowledge that symptoms appear between 6 
and 48 hours after arrival and resolve within the first 3 days [48]. 
 
Located on the high plateau of Antarctica at an elevation of 2,835 m (9,300 ft), the environment 
of South Pole Station closely reflects the 8.2/34 environment as well as the operational profile of 
NASA mission scenarios. Most jobs at South Pole Station require physical activity, with a 
significant portion of personnel working outdoors. Activities include construction, heavy 
equipment operation, transport of supplies, science support, research, and fuel delivery [48]. This 
environment could serve as a high-fidelity, ground-based analog with which to research hypoxic 
effects within a true mission-like environment. 
 
 
 
 
Figure 1. Percentage of participants who reached their maximum LLSQ symptom 
score during the first 7 days at South Pole Station (2,835 m [9,300 ft]) [48]. 
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4.4.1 AMS Risk Specific to 8.2/34 Condition 
It appears through an extensive literature search [49] and statistical analysis of available data [8] 
that the 1,830-m (6,000-ft) EAA computed for the initial 8.0/32 environment may have a greater 
risk of AMS than one would expect at this altitude. This independent pressure effect on true 
hypoxic dose appears real and has been suspected since 1946. Since the derivation of the alveolar 
gas equation was published [50], there has been a physiologically founded expectation of 
different outcomes under normobaric and hypobaric hypoxia given the same hypoxic PIO2, 
termed the nitrogen dilution or the respiratory exchange ratio effect [51]. In the current context, 
there are two cases: the first is the equivalent air altitude case with assumed exposure to 1,830-m 
(6,000-ft, 11.8 psia) breathing air (21% O2), and the second is the exploration atmosphere case 
with exposure to 4,877 m (16,000 ft, 8.0 psia) at 32% O2. The difference between these two 
exposures is 3,048 m (10,000 ft), but the PIO2 is identical at 117 mmHg, and it appears that the 
risk of AMS is greater in the exploration atmosphere case due to the lower total pressure [8]. 
Without considering acclimatization to mild hypoxia from one vehicle to the next, there is 
approximately a 25% probability of AMS per crewmember for the initial 8.0/32 environment and 
approximately a 10% probability of AMS for the proposed 8.2/34 environment [8]; this also 
assumes no further negative interactions due to adaptation to microgravity. 
 
Research is justified to measure the acute mild hypoxic response to the 8.2/34 environment. It 
seems that the magnitude of the pressure effect on true hypoxic dose is a function of the hypoxic 
PIO2. The pressure difference between 11.8 and 8.0 psia may or may not be sufficient to measure 
 
Figure 2. Severity of the most commonly reported symptoms over the first week of exposure in 
personnel rapidly transported to the South Pole (2,835 m [9,300 ft]) [48]. 
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a pressure effect on the onset, intensity, and incidence of AMS, given a reasonable sample of 
human subjects. If time and money resources are not available, staged decompression and 
pharmacological mitigation strategies should be developed to reduce and manage the predicted 
risk of AMS.  
 
4.5 Exercise Performance 
Exercise is a primary countermeasure for many of the negative physiological changes associated 
with spaceflight. Any expected change to exercise performance, such as mild hypobaric hypoxia, 
will need to be evaluated to determine if there are difference exercise countermeasures required 
during use of the 8.2/34 environment. 
4.5.1 Exercise Performance during Spaceflight 
Maintenance of exercise performance is of crucial importance for mobility of astronauts during 
long-duration missions and upon return to 1-g. Despite crew allocation of approximately 2.5 
hours per day to exercise, current exercise countermeasures are not fully effective in protecting 
against spaceflight-induced decrements in muscle, cardiovascular function, and bone health. For 
example, ISS crewmembers (Expeditions 1 through 15, n = 18) demonstrated mean decreases in 
isokinetic knee extensor and flexor strength of 11% and 17%, respectively [52], 10% reductions 
in maximal aerobic capacity [53], and 2% to 7% decreases (depending on site) in bone [54]. 
Recent analysis, including data from crewmembers with access to the advanced resistive exercise 
device (ARED), demonstrates that resistive exercise using ARED combined with adequate 
dietary intake has been even more effective in preserving bone mineral content and lean body 
mass [55]. It is now generally perceived that the current exercise countermeasure suite is 
effective in preserving muscle strength and aerobic performance if protocols are adhered to and 
adequate nutritional intake is maintained. There is a need to prevent spaceflight-related 
deconditioning to protect the health and mission readiness of current ISS crew as well as to 
enable NASA to protect the fitness of longer-duration astronauts on moon, Mars, and NEO 
missions. 
 
4.5.2 Exercise Performance and Hypoxia 
Exposure to hypoxia is associated with a number of adaptive responses, which could act 
synergistically with microgravity to further impair muscle and exercise performance. Acutely, 
acclimatization to a moderate altitude, e.g., 3,048 m (10,000 ft), takes approximately 3 weeks, 
during which time there is impairment in exercise performance due to decreased cardiac output, 
increased ventilation, and muscle fatigue [56] [57]. A decrease in the ability to perform exercise 
countermeasures early in flight may have negative consequences, as a large portion of the 
strength loss and muscle atrophy observed in ISS crewmembers may occur during the first few 
weeks in microgravity. Chronic exposure (> 3 weeks) to the 8/32 environment may also magnify 
microgravity-induced changes in muscle and exercise performance. For example, exposure to 
moderate altitude accelerates muscle atrophy [58] and the transition from the slow-to-fast-twitch 
fiber type [59] decrease mitochondrial function and aerobic metabolism [60] and increase muscle 
fatigability [61]. Ultimately, there is a 0.5% reduction in aerobic power output per 100 m (328 ft) 
of elevation [61] [62] [63] [64]. Moreover, similar to microgravity, individuals with higher 
aerobic capacity are more affected by hypoxic exposure [65], and there are gender differences in 
performance [66] [67] [68] as well. 
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4.5.3 Cardiovascular System Performance and Spaceflight 
Alterations in cardiovascular function have been reported following both acute and chronic 
exposure to spaceflight and are thought to be secondary to circulatory unloading mediated by a 
central redistribution of fluid and an accompanied reduction in plasma volume. It is now 
accepted that these adjustments contribute to the increased risk of orthostatic intolerance and 
underlie the reduction in exercise capacity experienced by some astronauts. More recent studies 
using both ultrasound and cardiac magnetic resonance imaging have elucidated a number of 
structural and functional changes, including left ventricular diastolic dysfunction, cardiac atrophy 
/ remodeling (an average decrease of approximately 1 gram per week), and vascular / endothelial 
dysfunction, which is differentially altered between cerebral and peripheral vascular beds. 
 
4.5.4 Cardiovascular System Performance and Hypoxia 
The cardiovascular control systems are keenly sensitive to changes in both O2 and CO2. While 
there is no literature on the specific environment in question (8/32) combined with a stressor 
such as spaceflight, there is a relatively rich literature base on the effects of hypoxia (including 
relatively mild hypoxia) here on Earth. A preliminary review of this literature revealed that 
chronic exposure to extreme HH, such as that experienced at altitudes at or above 3,400 m 
(11,154 ft), may impart protective adaptive effects on the cardiovascular system. On the other 
hand, acute or intermittent exposure to such conditions, even at altitudes that provide only 
modest hypoxia, may impart maladaptive responses. Specifically, Holloway, et al. demonstrated 
reduced left ventricular mass (approximately 11%) and impaired diastolic function in sea level-
dwelling subjects after only a short and gradual ascent to the 5,300-m (17,388-ft) Mt. Everest 
Base Camp [69]. It was postulated that such changes were due to alterations in myocardial 
energetics, particularly reduced levels of phosphocreatine and adenosine triphosphate. Such 
results confirm and provide a mechanistic insight into an earlier finding by Kjaergaard and 
colleagues, who demonstrated that cardiovascular function was depressed even after only 18 
hours of exposure to simulated hypoxia comparable to living at 4,000 m (13,123 ft) [70]. Papers 
by Nishimura [71] and Iwasaki [72] suggest that a relative altitude as low as 2,000 m (6,562 ft) is 
sufficient to alter vascular function in the brain in as little as 5 hours. 
 
It is likely that many of these effects are mediated, at least in part, by hypoxia-inducible factor 1 
(HIF-1) [73] [74]. There is also evidence that HIF-1 interacts with reactive O2 species to form a 
positive feedback loop, thus exacerbating any oxidative stress already present during spaceflight. 
 
4.5.5 Exercise and Cardiovascular Performance Conclusion 
Acute and chronic exposure to the 8.2/34 environment may exacerbate microgravity-induced 
decrements in muscle and exercise performance. The relative impact of these changes is highly 
duration-dependent. Acute studies are needed to compare muscle and cardiovascular 
performance at 8.2/34, probably using NH simulations to determine pre- and in-flight exercise 
prescriptions. Long-duration 8.2/34 exposure would prompt the need for additional adaptation 
studies. 
 
An Exploration equivalent to the ISS Crew Health Care System (CHeCS) will consist of 
countermeasures, environmental health monitoring, and health maintenance. The impact of an 
8.2/34 environment will have to be evaluated in terms of each of these elements. 
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The Countermeasures System (CMS) will provide aerobic and anaerobic exercise capabilities for 
crewmembers to minimize cardiovascular deconditioning, bone loss, and muscle atrophy due to 
disuse in microgravity. In general, the current CMS on the ISS is believed to be adequate for 
maintaining aerobic fitness and bone mineral density (although preservation of bone architecture 
is still being debated). However, CMS hardware may be reduced in exploration missions given a 
smaller habitable volume compared with the ISS. A specific concern associated with the 8.2/34 
environment is that air pressure-dependent hardware, such as the ARED, would work less 
effectively, requiring more mass and/or more frequent cylinder evacuations to maintain the same 
range of resistance. 
 
Exercise protocols of lower intensity or shorter duration [44] have been proposed for an 8/32 
environment to preserve consumables and minimize hardware cycling, while reducing the risk of 
AMS, as exercise has been associated with more severe AMS symptoms at simulated altitude 
[46]. However, these potential benefits of reduced exercise protocols must be weighed against 
the risks of cardiovascular and musculoskeletal deconditioning in terms of ability to perform 
strenuous mission tasks (e.g., EVA) and long-term health consequences. 
 
4.6 Immune System Function 
We know that reactivation of latent herpes viruses occurs during short-duration spaceflights [75]. 
Recent data from the ISS indicate that in-flight dysregulation of the immune system persists for 
the duration of a 6-month mission [76]. Persistent immune dysregulation during exploration 
missions could increase certain health risks to astronauts, including infectious disease, allergy 
and hypersensitivities, malignancies, autoimmune manifestations, and the consequences of 
continued viral reactivation [77]. 
 
There is ample terrestrial evidence demonstrating that hypoxia may also adversely influence the 
immune system. We also know that T cell function is impaired during hypoxic stress [78] [79] 
and that hypoxia promotes the accumulation of extracellular adenosine as a result of enhanced 
purine nucleotide degradation from adenosine tri- and diphosphate (ATP, ADP). Binding of 
adenosine to the cAMP-elevating Gs protein-coupled A2 receptors results in an inhibition of 
effector functions of T cells and myeloid cells and includes the inhibition of expansion and 
secretion of cytotoxic molecules and cytokines [80]. This suppresses the immune system and 
thus may render the body more susceptible to some of the adverse health consequences described 
above.  
 
The combined immune-suppressive effects of spaceflight environmental factors and even a 
short-term and rather mild hypoxic atmosphere is therefore of much concern. The spaceflight 
effects per se might be controllable even during long-term missions, but the additive and/or 
synergistic effects of an 8.2/34 hypoxic environment might further dysregulate immune 
parameters, thus rendering the consequences of immune deficiencies less controllable. Thus, 
forward work investigating the degree to which an additive and/or synergistic effect of the well-
known spaceflight environmental factors and 8.2/34 hypoxia occurs is highly recommended 
before planning for long-duration deep space missions. 
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4.7 Oxidative Stress and Damage 
There is evidence that spaceflight-induced oxidative stress and damage (OSaD) is a component 
of the following spaceflight-related effects: immune manifestations, decreases in bone and 
muscle strength, and development of the VIIP syndrome during spaceflight [81] [82] [83] [84] 
[85] [86] [87] [88] [89]. OSaD is the result of organic and systemic dysregulation of the free 
radical normalization and scavenging process and is also the cause of many different 
manifestations of disease, including atherosclerosis [90] [91] [92]. Therefore, during long-
duration missions into deep space, OSaD could likely constitute an important mechanism for 
development of cardiac disease [90] [93] [91] [94]. 
 
Changing the environment during spaceflight to an 8/32/34 environment will lead to mild 
hypoxia, which is known to further promote OSaD [95] [96]. The combination of spaceflight 
(radiation and weightlessness) and hypoxia will be a hazard that will likely induce augmented 
synergistic and additive OSaD effects, thereby rendering immune dysfunction, bone 
demineralization, muscle degradation, and the VIIP syndrome less controllable – even with use 
of the current countermeasures. Therefore, OSaD research is warranted to determine whether it is 
safe for the astronauts to change the vehicle environment to a lower O2 partial pressure during 
spaceflight [97] [98] [88]. Such research should be combined with the suggested research 
scenarios within the immune discipline [99]. 
 
Given that the main motivation behind a reduced environment such as 8.2/34 is to facilitate 
frequent EVAs, several general concerns regarding the performance of frequent EVAs are 
discussed below. 
  
First, repeated cycling between suit pressure and habitable volume pressure could have 
detrimental effects on the crew. Intermittent hypoxia, defined as repeated episodes of hypoxia 
interspersed with episodes of normoxia, has been studied to enhance exercise performance in 
athletes, as the so-called “live high and train low” method can stimulate erythropoietin and red 
blood cell production and increase ventilation [100]. However, intermittent induced cyclic 
hypoxia is also associated with increased arterial blood pressure through activation of the renin-
angiotensin system in healthy subjects [101] and enhanced sympathetic and blood pressure 
responses to acute hypoxia and hypercapnia [100]. Cumulative exposure to intermittent hypoxia 
may yield progressive brain injury and subsequent neurological impairment due to metabolic 
stresses and reactive free radicals during hypoxia [100]. Intermittent hypoxia appears to elicit the 
same ventilatory changes to hypoxia as chronic hypoxia and also changes the surface receptors 
on red blood cells, which may cause long-term changes in VO2 max [102]. Furthermore, patients 
with obstructive sleep apnea, who serve as a model for chronic intermittent hypoxia, have a high 
risk of cardiovascular disease, increased levels of inflammatory markers, oxidative stress, 
coagulation, and thrombosis [103] [104].  
 
4.8 Sleep 
The introduction of an 8.2/34 environment may have implications for sleep in microgravity. In 
particular, difficulties in sleep are anticipated in hypoxic environments during the acclimatization 
phase.  
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4.8.1 Sleep during Spaceflight 
Sleep deprivation is associated with degraded performance of neurobehavioral tasks, as well as 
decrements in health and well-being; thus, any stressor that has the potential to affect the quality 
of sleep during a mission could be detrimental to the astronaut. Studies have shown that sleep is 
reduced to an average nightly duration of 6 hours in short-duration missions (i.e., Space Shuttle), 
despite schedule requirements that accommodate 8 hours of sleep per night [105] [106]. Duration 
may not be the only aspect of sleep that is currently affected in spaceflight. Shuttle astronauts 
reported poor sleep quality on orbit [107]. Few studies have objectively looked at sleep structure 
in space, but those that have evaluated sleep stages have found changes, although these studies 
included only a small number of participants [106] [108]. Ground research demonstrates that 
changes in sleep structure are associated with health and performance decrements [106] [108] 
[109] [110]. Reduced sleep and possibly altered sleep structure already pose implications for 
cognition, alertness, and performance on critical tasks.  
 
4.8.2 Sleep and Hypoxia 
Terrestrial studies indicate that hypoxic environments can yield similar detriments to sleep as 
those that have been seen in the spaceflight environment, particularly field studies that include 
high workloads and increased exertion. Thus, the combination of adding a hypoxic environment 
to existing stressors associated with sleep in space could potentially exacerbate these negative 
effects. 
The lowest altitude at which sleep and/or post-sleep performance are affected is not definitively 
known. Decreased quality of sleep has been reported after acute ascent to altitudes of North 
American ski resorts (2,000 to 3,000 m) (6,561 to 9,843 ft) and higher. Changes in sleep 
architecture include a shift toward lighter sleep stages, with marked decrements in slow-wave 
sleep and variable decreases in rapid-eye-movement sleep [111]. Accordingly, the sleep quality 
at these altitudes was perceived as poor, with the sensation of occasional awakenings, a sense of 
suffocation caused by periodic breathing relieved by a few deep breaths, and resumption of 
sleep.  
 
Weil proposed that respiratory periodicity (arousals) at altitude results from alternating 
respiratory stimulation by hypoxia and subsequent inhibition by hyperventilation-induced 
hypocapnia [111]. Despite approximately the same sleep duration, upon arising from sleep, 
subjects reported impressions of greatly abbreviated and restless sleep. Additionally, during 
wakefulness, subjects experienced drowsiness [111]. This relationship may need further 
evaluation because CO2 levels are several times greater on the ISS than on Earth [11]. 
 
Studies in simulated environments, however, revealed less conclusive effects on sleep and 
related outcomes. Muhm, et al. studied post-sleep neurobehavioral performance decrements at a 
simulated altitude of 2,438 m (8,000 ft) on O2 saturation, heart rate, sleep duration, sleep quality, 
post-sleep neurobehavioral performance, and mood [112]. Results showed that SaO2 before sleep 
was significantly lower at altitude than at sea level. During sleep, SpO2 decreased further at both 
altitude and ground. SaO2 was below 90% during 44.4% of the time at altitude and 0.1% of the 
time at sea level. Subjects participated in three 18-hour sessions, and sleep was more disturbed in 
the first study session than in subsequent sessions (potentially an argument for pre-adaptation 
before flight), and older subjects had more disturbed sleep. Despite these findings, objective and 
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subjective measurements of sleep duration and quality did not differ significantly with altitude or 
post-sleep neurobehavioral performance and mood.  
 
Thomas, et al. found that sleep at a simulated altitude of 3,962 m (13,000 ft) was not associated 
with decrements in working memory or simple reaction time in healthy non-smoking men and 
women [113]. Weiss, et al. found no difference after hypoxia in sleepiness, encoding, verbal 
learning, objective vigilance, attention, or working memory at the same altitude with intermittent 
9-hour exposures for 28 consecutive nights [114]. While these results were unexpected, they 
highlight the limitations of simulated studies, possibly because they lack the conditions of high 
workload and exertion found in field studies and the spaceflight environment.  
 
Evidence indicates that sleep is significantly reduced during the time before an EVA [105]. 
Before an EVA, it is common for crewmembers to be too “wired” to sleep [107]. General 
practice has been not to schedule 2 consecutive days of EVA unless resources are limited. The 
proposed mission scenario with an EVA every day or every other day can result in a heightened 
stress response, reduced sleep, and/or interrupted sleep in addition to the already reduced sleep in 
microgravity. This could have implications for, e.g., task performance, memory, and cognition. 
 
4.9 Decompression Sickness 
Mitigation of DCS is one of the primary reasons for the selection of a non-sea-level environment. 
When coupling the 8.2/34 Exploration Atmosphere with a variable-pressure EVA suit and a 
highly efficient suit donning/doffing technology such as the Multi Mission Space Exploration 
Vehicle (MMSEV) suitports, crew time and consumable use are efficiently maximized [115]. 
To date, all predictions of the time and duration needed to effectively mitigate DCS using the 
8.2/34 environment have been derived from modeling data. Prior to use in-flight, the O2 PB 
requirements for transitioning between the 8.2/34 environment and a 4.3 psia EVA suit will need 
to be validated through a ground-based chamber test.  
This test will need to validate the requirements for the following: 
1. Transitioning from 14.7/21 to 8.2/34 without any risk of DCS 
2. Duration needed to saturate at 8.2/34 prior to the first EVA or additional PB requirements 
for the first EVA 
3. Nominal EVA PB requirements once saturated at 8.2/34 
4.10 Stand-Alone Hypobaric Effects 
Although the majority of human concerns regarding the 8.2/34 environment are related to the 
mild hypoxia, there are specific concerns related just to operating at a lower-pressure 
environment. For instance, reduction in pressure alone will account for an increased insensible 
water loss that will need to be replaced with additional drinking water [116]. This increased 
water loss will also need to be considered by the ECLSS team. 
4.10.1 Hypobaric Effects on Medical Equipment 
The Health Maintenance System (HMS) will enable nominal and contingency evaluation of crew 
health and provide treatment for a variety of illnesses and injuries. All medical hardware will 
also need to be certified to operate in an 8.2/34 environment. Additionally, air-dependent 
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diagnostic hardware may have to be modified (e.g., blood pressure cuffs) or substituted with 
devices that are not air-dependent (e.g., air-puff tonometer). In terms of therapeutics, 
medications may or may not be more stable in a reduced O2 environment in combination with the 
higher space radiation levels. Capabilities for supplemental O2 and mechanical ventilation will 
be needed to treat a subset of conditions on the Exploration Medical Conditions List, and both 
will have to be compatible with the spacecraft atmosphere. A defibrillator to treat sudden cardiac 
arrest or arrhythmia will also have to pose minimal fire risk. 
 
The purpose of the Space Medicine Exploration Condition List (SMEMCL; JSC-65722) is to 
serve as an evidence-based foundation for determining which medical conditions could affect a 
crewmember during a given mission profile, which of those conditions would be of concern and 
require treatment, and the conditions for which a gap in knowledge or technology development 
exists. This information will be used to focus research efforts and technology development. 
Atmospheric changes from sea level to 8.2/34 will change the incidence of diseases currently 
being researched, such as AMS, and the treatment of diseases not directly induced by hypoxia, 
such as a pneumothorax, which requires increased O2 for treatment.  
 
The Integrated Medical Model is a stochastic model that uses Monte Carlo methodology to 
simulate medical events and estimate the impact of these medical events for a given DRM. 
Outcomes include Crew Health Index (CHI), probability of evacuation (EVAC), and probability 
of loss of crew life (LOCL). For each DRM, 20,000 trials are simulated and probability 
distributions for CHI, EVAC, and LOCL are determined. Thus, a change in cabin pressure will 
directly affect diseases such as AMS and DCS, as well as affect the consequence of O2-
dependent diseases such as respiratory infection and anemia. 
 
Treatment of these O2-dependent diseases requires directed delivery of concentrated O2. This 
capability may be impaired by a lower ambient cabin pressure and higher O2 concentration.  
 
4.10.2 Hypobaric Effects on Food Preparation 
 
In the currently used prepackaged food system, oxygen transfer through food packaging may 
cause oxidation, resulting in quality loss, including nutrient breakdown and color and flavor 
changes. There is actually a potential advantage of the 8.2/34 environment because there would 
be less O2 to deteriorate the food. Once technology gap is the degree to which the 8.2/34 
environment affects product quality and whether the packaging barrier requirements need to be 
significantly modified. 
 
On a surface mission, a partially bioregenerative or bulk food system may be implemented, 
which would include some food processing and preparation. The 8.2/34 environment can affect 
operations during an exploration mission when food preparation is conducted. At reduced 
pressure conditions, water boils at much lower temperatures, which slows the heat transfer in 
food and water.  At this lower pressure, the boiling temperature for water is 84°C (183°F). To 
create safe and acceptable food, cooking and processing of food are dependent on 
time/temperature combinations. Additionally, certain resulting textures come from cooking. For 
example, if the starch in rice is not gelatinized at 83°C (181°F), the rubbery texture is replaced 
by dry, granular textures. The Advanced Food Technology (AFT) team has not conducted any 
Risk of Hypoxia from the Exploration Atmosphere 
24 
 
tests at 8.2 psi, so there are no data on what would be required under these unique conditions.  A 
solution may be to use a pressure cooker, but that requires extra mass and volume and may not 
be the answer for all types of “cooking.” Understanding the physical changes in the environment 
and the impact on food preparation and processing is critical to ensure that food remains 
acceptable to support consistent caloric and nutritional intake and to ensure the food remains 
safe. There is a gap in knowledge regarding acceptability of the food and the microbial load 
throughout food processing in these conditions, which needs to be filled to quantify the risk of 
under-consumption due to unacceptable food or of foodborne illness due to unsafe food. In the 
event that knowledge in this area identifies a risk in food safety or acceptability, there would be 
an associated technology gap formed to reduce the risk to acceptable levels.  
 
The combination of hypogravity and lower pressure may improve colloidal stability, but mixing, 
fluid transport, boiling, condensation, and natural convection are all processes likely to be 
negatively affected by the reduction in gravity. Thus, any equipment evaluation must consider 
whether the equipment depends on physical phenomena that fail to exist in a hypogravity or 
hypobaric environment.  
5 Risk in Context of Exploration Mission Operational 
Scenarios    
As of August 2013, there have been no reported cases of DCS during Shuttle and ISS missions 
due to adherence to PB protocols that have been rigorously developed and validated specific to 
Shuttle and ISS operational environments and EVA scenarios. Although DCS risk has been 
greatly reduced through these PB protocols, it is at the expense of significant crew time and 
consumable usage. This need for significant crew time and consumables will not meet the needs 
of an exploration program with robust EVA plans. To enable a robust EVA plan, an exploration 
atmosphere of 8.2 psia with 34% O2 has been proposed. 
5.1 Transitioning Guidelines between different Atmospheres will 
Need to be Developed 
This section summarizes some suggested mitigation strategies that will help alleviate symptoms 
or prepare the astronaut to occupy the 8.2/34 spaceflight environment. Gradual decompression 
from 14.7 psia to 8.2 psia will diminish many of the acute symptoms, such as AMS and hypoxic-
related sleep problems. Supplemental O2 should be available during vehicle decompressions and 
throughout the length of the mission in case certain crewmembers do not adapt as readily as 
others. This supplemental O2 will also be used as DCS prevention during this depressurization. 
 
An exact understanding of atmospheric and tissue inert gas exchange does not yet exist to 
precisely define when the inert gas tension in tissues comes into a new equilibrium after the 
breathing environment has changed. When a significant pressure reduction is used to reduce the 
tissue N2 tension, there is an additional complication of creating “silent bubbles” in the body that 
then hinder normal tissue N2 exchange with the atmosphere. In the case of the 8.2/34 
environment, the pressure reduction from 14.7 psia to 8.2 psia is conducted in tandem with an 
increase in FIO2 from 21% to 34%. Both of these changes reduce the ambient ppN2 from 11.6 
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psia to 5.4 psia (600 to 280 mmHg), but there is some uncertainty regarding the time at which the 
tissue N2 tension comes into a new equilibrium. If we accept that a 360-minute theoretical half-
time tissue compartment is key to our DCS applications, basic exponential decay principles 
indicate the need for four half-times (24 hr) to account for 94% of the difference between the 
initial and final tissue N2 tension. Six half-times (36 hr) brings the difference to 98%, and by 8 
half times (48 hr), the difference is negligible.  
 
Based on research experience from the 10.2 psia staged denitrogenation protocol in the Shuttle 
program, it was clear that a direct decompression to 10.2 psia created “silent bubbles” that 
manifested 12 to 16 hours later as early-onset venous gas emboli (VGE) and early-onset Type II 
DCS symptoms while at the EVA pressure of 4.3 psia. A 60-minute PB was instituted such that 
the first decompression to 10.2 psia would not theoretically supersaturate the 360-minute half-
time compartment; the computed tissue ratio was 1.0. This removed the early-onset VGE and 
DCS in subsequent tests of the staged protocol [117]. In keeping with this same philosophy, 
preliminary analysis indicates the need to implement a 180-minute PB before depressurization 
from 14.7 to 8.2 psia to keep the computed tissue ratio at 1.0. Because 100% O2 is used for the 
180-minute PB, the tissue N2 tension is lower than it would be if the astronaut was just exposed 
for 180 minutes to the 8.2/34 environment. Thus, the computed time required to achieve 
equilibrium with the 8.2/34 environment is reduced from 48 to 45 hours. If an EVA is performed 
before tissue N2 equilibration at 8.2/34, additional PB beyond the expected 15 minutes would be 
needed, possibly as much as 30 minutes for the first EVA.  
 
Crewmembers will need to be trained to understand the symptoms of hypoxia. When the 
application of the 8.2/34 environment is to be employed early in the mission phase, the 
crewmembers will have to adapt acutely to the spaceflight and hypoxic environment at the same 
time. Critical tasks should be avoided, and workload stress should remain low during the 
atmospheric transition period.  
 
Although hypoxic pre-conditioning is not a mitigation strategy for DCS, it is a technique that 
uses bouts of hypoxic exposure to prevent ischemia. This may not directly apply to the astronaut 
in the spaceflight environment, but the effect of pre-exposure to the hypoxic stimulus and the 
way in which it prepares people to tolerate the hypoxic environment on subsequent trials have 
also been discussed. The degree of hypoxia, duration of exposure, and timing of the exposure 
would need further literature review before implementation of the technique in the crew training 
and mission preparation phases.  
 
5.2 Exploration Missions involve Increased EVA Capability that is 
Required at Very Different Points in Different Design Reference 
Missions 
The planned scenarios currently being considered for future missions using the 8.2/34 
environment involve a high number of EVAs. Although all of these scenarios include a phase 
requiring numerous EVAs, this phase may take place at very different points in a mission. 
Crewmembers can reach the lunar surface or a Cis-Lunar location within a few days. On the 
other hand, it will take several months to reach a NEA or Mars. Therefore, we have to consider 
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the operational pace and known physiological changes as we investigate the potential impacts of 
the inclusion of the 8.2/34 environment.  
 
In the lunar and Cis-Lunar cases, spaceflight data from shuttle missions should be leveraged. In 
these cases, the transition to the 8.2/34 environment would superimpose adjustments to the 
hypobaric hypoxic environment with adjustments associated with adaptation to microgravity. 
The concern is that the combination of these adjustments in addition to a EVA-heavy mission 
profile may degrade the health and performance of astronauts, who must maintain a high level of 
proficiency to accomplish mission goals [44]. The first 2 weeks of a spaceflight is a period of 
dynamic physiological changes in the crewmember. Primarily, the physiological adaptation to 
the new spaceflight environment includes: cephalad fluid shift, neurovestibular adaptation, 
susceptibility to space motion sickness, and changes in spatial orientation. These changes result 
in physical symptoms such as increased fatigue, headaches, reduced sleep, lack of appetite, and 
back pain, all of which can negatively impact mood and behavior. Cognitive processes, such as 
focus and attention, memory recall, problem solving, and executive function, may affect mission 
operations, which include highly technical and complex procedures [118].  
 
Space Shuttle missions, which typically lasted approximately 2 weeks, were regarded as high-
workload and fast-paced missions, with little to no time available for “winding down” [107]. 
Crewmembers reported forgoing to eat and sleep to complete mission objectives [119] [107]. 
Accordingly, objective data from spaceflight indicate that shuttle astronauts slept an average of 
approximately 6 hours per night [105]. The increase in stress response and sleep deprivation 
increases the likelihood of errors. Therefore, effects of the slightly hypoxic environment must be 
considered with these operational data in mind. It could be expected that more severe detriments 
would result from the inclusion of a hypoxic environment. 
 
In the NEA and Mars cases, spaceflight data from ISS missions will be more appropriate for 
analysis. It will take up to 6 months to reach these locations, which nicely parallels the current 
length of an ISS mission. At the end of a 6-month ISS rotation, crewmembers are acclimatized to 
the spaceflight microgravity environment; therefore, the problem of complicating the adaptation 
to spaceflight with the 8.2/34 environment is avoided. However, the long-term issues associated 
with spaceflight will pose different challenges. Crewmembers may have signs or symptoms of 
the VIIP syndrome. They may have decrements in cardiovascular, muscular, and aerobic 
capacity if the current ISS countermeasure effectiveness cannot be maintained during transit. 
Transitioning to the 8.2/34 environment in the midst of returning to a gravity environment (3/8-g 
on Mars) and adding an EVA-heavy phase to the mission after months in space is a scenario in 
which we have no operational experience. Expected problems are less likely going to stem from 
acute overload and are more likely to derive from the combination of negative chronic 
spaceflight adaptation, which may worsen with exposure to a mildly hypoxic environment 
coupled with an increased EVA frequency. 
 
5.3 Exploration Atmosphere Enables New EVA Architecture 
While it may be feasible to enable the means to transition into the EVA environment with 
significantly less overhead, there remain many unknown questions related to the risk of 
crewmember injury and performance during an EVA. To date, there have been relatively few 
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EVAs performed during any one NASA mission across any flight program. The largest number 
of EVAs during any single mission has been 10. STS-61, 82, 109, and 125 each had 10 EVAs 
over 5 consecutive days spread across 4 crewmembers using the shuttle staged protocol. STS-
123 included 10 EVAs spread across 10 days and 4 crewmembers, and STS-127 had 10 EVAs 
spread across 10 days and 4 crewmembers. In each of these specific shuttle missions, no EVA 
crewmember completed more than 3 EVAs. 
 
The greatest number of EVAs for any individual crewmember during a short-term mission is 4. 
During STS-116, Robert Curbeam completed 4 EVAs over 7 days, with a day of recovery 
between each, and Scott Parazynski completed 4 EVAs over 9 days during STS-120. With regard 
to long-duration missions, Daniel Tani and Peggy Whitson completed 5 EVAs each from 11/9/07 
to 1/30/08 during ISS Increment 16, which is the most for any crewmember during any NASA 
mission. During Apollo 15, 16, and 17, each EVA crewmember performed 3 EVAs on 3 
consecutive days, which is the highest EVA density within NASA. 
 
There is no flight experience that replicates the types of scenarios being discussed for 
Exploration missions, with possibilities of multiple EVAs per day, tens to hundreds of EVAs 
over a mission, and single-person EVAs. All data available on crewmember performance and 
injury rates are limited to the previously described duration exposures as well as the numerous 
shorter exposures. Historically, EVA has been treated as a pinnacle career event, but the newer 
EVA architectures employing numerous EVAs may need to consider EVAs as routine mission 
events. Therefore, injury rates and performance limitations that have been tolerated to date may 
not be acceptable for future Exploration missions.  
 
There are also many technical questions to address. Until the recent ISS era, in which EVA suits 
are maintained on orbit and sized for each crewmember, the EVA suits were used for a specific 
mission and then returned to the ground with no required long-term maintenance in orbit. 
 
Currently, EVAs are some of the most grueling and physically and mentally demanding activities 
required during a space mission. On EVA day, the schedule only accommodates time for EVA, 
and the EVA astronaut is not required to exercise or complete other tasks. During EVAs, the 
crew is especially vulnerable to the space environment. A dramatic shift in the perception of the 
mission will occur during an EVA-heavy mission, where astronauts will routinely expose 
themselves to an especially harsh and physically and mentally stressful environment. Increased 
training, mental preparation, and safety vigilance will be necessary for such missions and may 
have implications for selection as well. 
 
5.4 No Exploration Atmosphere Means Longer Denitrogenation 
Protocols and Higher Consumable Usage 
Current and future spacesuit functionality requires decompression prior to EVA. Without the use 
of a staged denitrogenation protocol, such as that proposed with the 8.2/34 Exploration 
Atmosphere, or a zero-PB EVA suit operating at higher pressures, denitrogenation protocols will 
remain lengthy. Much research could be performed to reduce the length of existing ISS PB 
protocols. Understanding how a break in PB affects P(DCS) is a critical step. Additionally, 
understanding the differences in VGE, N2 washout, and micronuclei generation in the space 
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flight environment would be of great benefit. Ultimately, an operational mitigation strategy that 
relies on a long O2 PB as the primary strategy will result in longer, more complicated EVA 
preparation timelines and higher consumable use, as well as reduced flexibility and capabilities 
of Exploration EVAs.  
An example of the consumable savings available through use of the 8.2/34 Exploration 
Atmosphere is the reduction in the suit purge time by 6 min per EVA, achieving 80% O2 in the 
spacesuit rather than 95%. This modestly increases the P(DCS) risk, but the calculated savings of 
0.48 lb of gas and 6 minutes per person per EVA corresponds to more than 31 hours of crew time 
and 1800 lb of gas and tankage under the Constellation lunar architecture [115]. 
Of the available strategies to significantly reduce denitrogenation time while maintaining 
acceptable DCS risk, the Exploration Atmosphere strategy is more promising than either a high-
pressure EVA suit or an enhanced version of current ISS PB protocols.  
 
5.5 Carbon Dioxide Levels May Add Additional Negative Effects 
 
If exploration crews are exposed to similar CO2 levels as those on the ISS, the effect of 
hypercapnia combined with hypobaric hypoxia in hypogravity will also need to be researched. 
CO2 alone has widespread effects on human physiology, including: 
 Altering O2 binding: CO2 causes a rightward shift of the oxyhemoglobin saturation curve, 
such that at a given ppO2, less O2 is bound to hemoglobin, resulting in worsened hypoxia, 
especially during exercise or if a patient is in shock when O2 demand is increased.  
 Stimulating ventilatory response: CO2 not only increases minute volume and respiratory 
rate in the short term, but it also appears to alter the pH and CO2-dependent set point for 
respiratory drive after chronic exposure to CO2 [12].  
 Cerebral vasodilation: CO2 is a potent cerebral vasodilator and is linked to elevated 
intracranial pressure. Silwka [120] measured cerebral blood flow (CBF) in the middle 
cerebral artery in healthy subjects exposed to 0.7% and 1.2% CO2 environments for more 
than 23 days and found that CBF increased by as much as 35%; moreover, CBF did not 
return to baseline post-exposure. This persistence post-exposure is similar to the 
persistence of elevated intracranial pressure in some of the symptomatic astronauts who 
were subsequently diagnosed with VIIP, suggesting that CO2 may play a contributory or 
exacerbating role in the VIIP syndrome in long-duration spaceflight. 
 Altered bone homeostasis: CO2 exposure results in respiratory acidosis that appears to be 
compensated by the kidneys at higher levels (> 3% CO2) and by the bone at lower levels 
(0.5 to 1.5% CO2) [121]. The bone, which contains a large reserve of the body’s 
bicarbonate and calcium carbonate, serves as a buffer for acidosis; chronic acidosis can 
result in the release of calcium carbonate and bone breakdown [12]. In addition, chronic 
acidosis is associated with cell-mediated bone resorption and increased urinary calcium 
excretion due to stimulated osteoclastic activity and suppressed osteoblastic activity [122] 
[123] [124]. Thus, there is concern about chronic hypercapnia exacerbating an astronaut’s 
risk of developing kidney stones. 
 Behavioral health and performance: Anecdotally, ISS crewmembers have been noted by 
ground controllers to be more irritable or lethargic when they are gathered in a small 
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module for public affairs events, presumably due to local accumulation of CO2. 
Terrestrially, mild visuomotor impairment has been observed in subjects exposed to 1.2% 
CO2 [125]. Additionally, there appears to be a dose-response relationship between CO2 
level and symptoms such as nausea, dizziness, derealization, fear of losing control, and 
paresthesia [126]. 
 
5.6 All Assumptions Regarding use of the 8.2/34 Environment 
Assume N2 as the Primary Inert Gas 
 
A significant consideration for Mars exploration is the cost required to provide life support, 
particularly the atmospheric gases in the habitat, rover vehicle, and space suit. The 95.7% CO2 in 
the Martian atmosphere can be converted to O2 or even fuel for propulsion. The remaining major 
gas constituents are 2.7% N2 and 1.6% Argon (Ar). These inert gases, which can either be used 
at their existing ratio or separated and later blended to any desired concentration, must be 
considered as the alternative to transporting N2 from Earth [127]. 
 
 
An assumption is that an automated system could be sent to Mars before a manned flight to 
extract and store the thin Martian atmosphere, which exerts a total pressure of less than 5 mmHg.  
The system elements include, e.g., a vacuum pump, power supply, storage container, and control 
system.  From an engineering standpoint, the preference would be to not separate the N2 and Ar 
into different containers, as this process requires too much energy and technology. Therefore, the 
breathing atmosphere would include N2 and Ar at the 1.68 ratio already present in the Martian 
atmosphere, supplemented with a sufficient amount of O2 to achieve an acceptable total pressure. 
 
Given a N2 to Ar concentration ratio of 1.68 for the inert gas component of the Martian 
atmosphere, 2.7% N2 / 1.6% Ar = 1.68, the ratio of N2 and Ar pressures in a habitat that also 
results in a 1.68 concentration ratio is computed as: 
 
N2 pressure = (tigp × 1.68) / 2.68,         Eq. 1 
  where tigp is the total inert gas pressure. 
  
Consider the case of the current 8.2 psia habitat pressure with 34% O2 and 66% N2. The ambient 
ppO2 is 2.79 psia (0.34 × 8.2 psia). An alternative to this atmosphere is one with a binary inert 
gas composition. Using the Martian inert gas as is, Eq. 1 computes the required ppN2 in a habitat 
at 8.2 psia with 34% O2 to achieve the 1.68 N2-to-Ar ratio. The tigp in Eq. 1 is 5.412 psia (0.66 × 
8.2 psia). Solving Eq. 1 for N2 pressure yields 3.393 psia. The balance of inert gas is Ar at a 
ppAr of 2.019 psia. Converting these pressures to concentrations yields 34% O2, 41.3% N2, and 
24.6% Ar. 
  
An 8.2 psia atmosphere that contains aproximately 25% Ar is problematic if EVAs are 
performed at reduced pressure [128]. This potentially cost-effective in-situ resource approach 
would drive a risky and complicated EVA program in terms of managing DCS risk. This 
conclusion needs to be challenged with empirical data from well-designed human trials. 
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There are other alternatives to consider.  Nitrogen and Ar can be separated and stored in different 
containers to be blended to any atmospheric specification. The technical feasibility of this 
approach needs to be demonstrated and be cost-effective compared with just providing N2 from 
Earth. Finally, the N2 and Ar from the Martian atmosphere could be used during the return trip to 
Earth, as EVAs on the return trip would likely be infrequent. 
6 Gaps    
We have described much of the evidence related to the application of mild hypobaric hypoxia in 
space. The gaps are described in the following sub-sections and form the focus of the future 
NASA Human Research Program Exploration Atmosphere research efforts. 
Currently, there are few pre, in-, and post-flight data to characterize this risk. Below is a list of 
related unanswered issues that will help to define the VIIP syndrome and characterize the risk for 
exploration-class missions. 
 ExAt1 - We do not know how mild hypobaric hypoxia in combination with other 
spaceflight environmental factors will impact the brain (e.g., VIIP syndrome, 
sensorimotor performance, and AMS risk). 
 ExAt2 - We do not know how mild hypobaric hypoxia in combination with other 
spaceflight environmental factors will impact exercise countermeasures. 
 ExAt3 - We do not know how mild hypobaric hypoxia in combination with other 
spaceflight environmental factors will impact the immune system and oxidative stress 
and damage (OSaD). 
 ExAt4 - We do not know how mild hypobaric hypoxia in combination with other 
spaceflight environmental factors will impact sleep. 
 ExAt5 - We do not know the O2 prebreathe requirements for DCS mitigation associated 
with the 8.3/34 environment (Shared Gap with DCS5). 
 ExAt6 - We do not know how a hypobaric environment will affect medical equipment. 
 ExAt7 - We do not know how a hypobaric environment will affect food preparation. 
7 Conclusion 
EVA is at the core of a manned space exploration program. With the 8.2/34 environment, NASA 
gains the capability for efficient EVA with low DCS risk, but it also accrues the human health 
and performance risks associated with the addition of hypobaric hypoxia to the spaceflight 
environment. These risks include increased intracranial pressure, visual impairment, 
sensorimotor dysfunction, immune dysregulation, and oxidative damage. Forward work also 
includes validating the DCS mitigation strategy, ensuring quality sleep, identifying/treating 
AMS, developing new exercise protocols and possibly hardware, effectively preparing food at 
8.2 psia, and ensuring operation of medical equipment at 8.2/34. 
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9 List of acronyms 
1-G   Earth-normal gravity 
10.2 psia  cabin atmosphere used during Shuttle EVA operations 
14.7/21  normal sea-level atmosphere, 14.7 psia, 21% oxygen, nitrogen balance 
8/32% 2006 EAWG recommendation for future exploration atmosphere, 8 psia 
pressure, 32% oxygen, balance nitrogen 
8.2/34% Current exploration atmosphere, 8.2 psia pressure, 34% oxygen, nitrogen 
balance 
ADP adenosine diphosphate 
AMS   acute mountain sickness 
Ar   argon 
ARED   Advanced Resistive Exercise Device 
ASD    atrial septal defect 
AFT   Advanced Food Technology 
ATP   adenosine triphosphate 
CHeCS  Crew Health Care System 
CHI    Crew Health Index  
CMS   countermeasure system 
CNS   central nervous system 
CO2   carbon dioxide 
CSF   cerebrospinal fluid 
DCS   decompression sickness 
P   pressure difference 
DRM   design reference mission 
EAA   equivalent air altitude 
EAWG  Exploration Atmospheres Working Group 
EVA   extravehicular activity 
EVAC   evacuation 
ExMC    Exploration Medical Capability 
FIO2   inspired oxygen fraction 
ft   foot 
g   gravity 
HEOMD   Human Exploration and Operations Mission Directorate 
HH   hypobaric hypoxia  
HIF 1   hypoxia-inducible factor 1 
HMS   Health Maintenance System 
ICP intracranial pressure 
IMM  Integrated Medical Model 
ISS   International Space Station 
JSC   Johnson Space Center 
kg   kilogram 
k number of gas species in tissue 
lb   pounds 
LLSQ Lake Louise symptom questionnaire 
LOCL loss of crew life 
LSAH Lifetime Surveillance of Astronaut Health 
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G   microgravity 
m   meter 
min   minute 
ml   milliliter 
mmHg   millimeters of mercury (pressure) 
MMSEV   Multi Mission Space Exploration Vehicle 
n sample size 
NASA   National Aeronautics and Space Administration 
NBL   Neutral Buoyancy Laboratory 
NEA   near-Earth asteroid 
NEO   near-Earth object 
NH   normobaric hypoxia 
N2   nitrogen 
O2   oxygen 
OSaD    oxidative stress and damage  
P2   final pressure 
PB   atmospheric pressure 
PB   prebreathe 
P(DCS)  probability of decompression sickness 
pH   measure of the acidity or basicity 
PI Principal Investigator 
PIO2   inspired (wet) partial pressure of oxygen 
ppN2   partial pressure of nitrogen 
ppO2    partial pressure of oxygen 
PRD    Program Requirements Document 
psia   pounds per square inch absolute 
SaO2   arterial blood oxygen saturation 
SMEMCL   Space Medicine Exploration Condition List 
SpO2   blood oxygen saturation  
STPD   standard temperature (0 Celsius), pressure (1 ATM), dry gas  
STS   Space Transportation System 
VGE   venous gas emboli 
VIIP   visual impairment / intracranial pressure 
WEI   Work Efficiency Index 
